Biodegradable Microspheres for Transarterial Chemoembolization in Malignant Liver Disease

Area of Science:

• Interventional Radiology
• Oncology
• Biomaterials Science

Background:

• Transarterial chemoembolization (TACE) is a cornerstone therapy for malignant liver disease, providing localized treatment with reduced systemic exposure.
• Traditional embolic agents in TACE have limitations regarding temporary occlusion and precise drug delivery.
• Degradable microspheres (DMS) represent an advancement in embolic technology for TACE.

Purpose of the Study:

• To review the existing literature on the use of degradable microspheres in transarterial chemoembolization (DMS-TACE).
• To explore the potential advantages, clinical applications, tolerability, toxicity, and efficacy of DMS-TACE.
• To discuss the suitability of DMS-TACE for various stages of liver malignancies and compare it with traditional embolic agents.

Main Methods:

• Systematic review of published literature on DMS-TACE.
• Analysis of studies reporting on patient selection, procedural aspects, and outcomes.
• Evaluation of data on tolerability, adverse events, and tumor response rates.

Main Results:

• DMS-TACE provides temporary vessel occlusion and optimized chemotherapeutic drug delivery.
• The technique demonstrates versatility, suitable for intermediate and advanced stage liver cancers, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and metastases.
• Existing literature suggests favorable tolerability, toxicity profiles, and efficacy compared to traditional embolic agents.

Conclusions:

• DMS-TACE is a promising evolution of TACE, offering enhanced drug delivery and temporary occlusion.
• The technology shows broad applicability across different liver malignancy types and stages.
• Further research and clinical trials are warranted to fully establish the long-term benefits and optimal use of DMS-TACE.